Abstract
Current results of meta-analyses and randomized trials have not brought any proof of superiority of PCI or medical therapy in reduction of nonfatal MI or all-cause or cardiovascular mortality in patients with chronic stable oligosymp-tomatic coronary artery disease. Therefore, it is necessary to consider several sources of information in the therapeutic decision-making process, such as individual clinical presentation, extent of ischemia or atherosclerosis.
The evaluation of individual lesion or patient risk using modern invasive imaging methods and introduction of bio-resorbable technologies may play a significant role in this field in the near future. The role of an interventional cardiologist in situations where randomized data are lacking is critical and is based on a responsible choice of appropriate dia-gnostic and therapeutic strategy considering the best risk/benefit ratio for the patient.